Aktueller Stand der systemischen Rosazea-Therapie

Area of Science:

• Dermatology
• Pharmacology

Background:

• Systemic therapy is fundamental for managing moderate to severe papulopustular rosacea.
• Oral tetracyclines, particularly doxycycline, are established as primary treatments.
• Doxycycline 40 mg modified-release is currently the only approved formulation for anti-inflammatory dosing.

Purpose of the Study:

• To review the current landscape of systemic rosacea therapy.
• To highlight the role of doxycycline in rosacea management.
• To discuss alternative systemic agents and their limitations.

Main Methods:

• Review of existing studies and clinical data on systemic rosacea treatments.
• Analysis of the efficacy and approved indications of doxycycline.
• Evaluation of off-label systemic therapies.

Main Results:

• Daily, non-antibiotic dosing of doxycycline is increasingly prescribed as a first-line treatment.
• Combination therapy with topical treatments often enhances efficacy compared to monotherapy.
• Limited experience exists for alternative systemic agents like macrolides, isotretinoin, and carvedilol.

Conclusions:

• Doxycycline remains a cornerstone of systemic rosacea therapy.
• Non-antibiotic dosing regimens are gaining traction for papulopustular rosacea.
• Alternative systemic treatments should be reserved for specific cases due to limited data.